DRD2 and glioblastoma: Knockdown of DRD2 or inhibition with pharmacologic antagonists in glioblastoma, pituitary tumors, pancreatic and breast cancer cells leads to inhibition of proliferation and migration as well as anti-tumorigenic effects in number of different xenograft mouse models [11, 13–16].